To conclude, we believe that the identification and characterization of gene signatures, driver events, and pharmacogenomics in molecularly homogeneous subsets of patients is likely to advance effective drug development strategies in colorectal cancer. Many challenges must be overcome before genomic-driven trials and personalized cancer medicine can become a reality and supplant currently accepted modalities. As costs decrease for next-generation sequencing and other high-throughput technologies, the clinical and economic impact of genomic tests in colorectal cancer will need to be revisited.
By Rodrigo Dienstmann, MDRamon Salazar, MD, PhDJosep Tabernero, MD, PhD Mar 15, 2015
“The data, however, should be owned by the patient. Their Physician can help direct them on how to apply the information contained in WGS to maximize its benefits,” states Michael Tetreault, Editor of Concierge Medicine Today. “Patients need the ability to securely store, use, and understand genetic data.” Concierge Medicine Today advises this should be accomplished through physician involvement and technology that integrates genetic data into software applications [apps]. Software apps are now available that analyze genetic data and transform the data into actionable information that can have a real impact on health.
Colorectal cancer has been extensively molecularly characterized in recent years. In addition to furthering the understanding of biologic hallmarks of the disease, the ultimate goal of these studies has been to provide tools that would allow us to identify subgroups of colorectal cancer with prognostic and predictive implications, either for the anticipation of toxicity or for selection of the best therapy, or both. As a result of these efforts, multiple genomic tests have become available for clinical use in early-stage and advanced colorectal cancer. Goldstein and colleagues have carefully reviewed the cost-effectiveness of these tests in this issue of ONCOLOGY; their evaluation is timely, considering the widespread availability of high-throughput technologies for genomic profiling.READ FULL STORY …